Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Daily Values

Growth Metrics

Others

Lineage Cell Therapeutics (LCTX) Short term Debt (2020 - 2021)

Historic Short term Debt for Lineage Cell Therapeutics (LCTX) over the last 4 years, with Q1 2021 value amounting to $523000.0.

Lineage Cell Therapeutics' Short term Debt changed N/A to $523000.0 in Q1 2021 from the same period last year, while for Mar 2021 it was $523000.0, marking a year-over-year change of. This contributed to the annual value of $523000.0 for FY2020, which is N/A changed from last year.
Per Lineage Cell Therapeutics' latest filing, its Short term Debt stood at $523000.0 for Q1 2021.
Over the past 5 years, Lineage Cell Therapeutics' Short term Debt peaked at $523000.0 during Q2 2020, and registered a low of $523000.0 during Q2 2020.